Sydney, Australia 11 September 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Orphan Drug Designation (ODD) request with the U.S. Food and Drug Administration (FDA) for 64Cu-SARTATE™, a diagnostic for the clinical management of neuroendocrine tumours (NETs). NETs are a…
Sydney, Australia 3 September 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 1-2a theranostic (i.e. diagnostic and therapy) trial with 64Cu-SARTATE™ and 67Cu-SARTATE™ in…
Sydney, Australia 30 July 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Robert Vickery as Chief Financial Officer. Robert is a transaction and change focused finance executive with over 30 years of experience and extensive involvement in life sciences and early stage…
Sydney, Australia 8 May 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed its anticipated capital raising of $10,000,005.50. This includes the previously announced strategic investment of $5,000,002.75 from GenesisCare, the largest private provider of cancer treatment in Australia and Europe, an…
Clarity Pharmaceuticals was featured in Idaho State University News. The Idaho State University Accelerator Center is Clarity’s partner for the production of Copper-67. The article discusses the developments in copper-67 production and the positive effects it has on the expansion of our clinical development program. Read the full article here: https://www.isu.edu/news/2019-spring/isu-idaho-accelerator-center-announces-record-production-of-form-of-medical-isotope-copper-67-that-will-be-used-in-cancer-clinical-trials.html/
Sydney, Australia 10 April 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear has joined Clarity’s Board following his recent appointment to their Scientific Advisory Board in August 2018 (Clarity Announcement dated 23 August 2018). Dr O’Bryan-Tear joined the pharmaceutical industry in…
Sydney, Australia 3 April 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce changes to its senior executive team to help its focus on commercial development and execution of its pipeline of radiopharmaceutical products for the treatment of children and adults with cancer. Dr Matt Harris,…
Sydney, Australia 26 March 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is delighted to announce that Dr Thomas Ramdahl will join Clarity’s Board. Dr Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and the first CEO of…
Sydney, Australia 28 February 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is delighted to announce that Dr Robert Miller will be working part-time as Consultant Chief Medical Officer. Dr Miller joined the pharmaceutical industry in 1988 and is a Managing Partner in Artemida Pharma Limited a drug development consultancy…
Sydney, Australia 18 February 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has raised a total of $8,965,959.75. This includes the previously announced strategic investment of $5,000,002.75 from GenesisCare, the largest private provider of cancer treatment in Australia and Europe, and an additional $3,965,957.00…